Similar articles for PMID: 36657979

Year	Number of Results
1999	1
2002	2
2004	6
2006	1
2008	1
2009	2
2010	3
2011	5
2012	8
2013	8
2014	3
2015	6
2016	11
2017	9
2018	13
2019	15
2020	18
2021	28
2022	29
2023	8
2024	0

1

Preliminary Clinical Experience with Cholecystokinin-2 Receptor PET/CT Using the ⁶⁸Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Medullary Thyroid Cancer.

von Guggenberg E, Uprimny C, Klinger M, Warwitz B, Sviridenko A, Bayerschmidt S, di Santo G, Virgolini IJ. von Guggenberg E, et al. J Nucl Med. 2023 Jun;64(6):859-862. doi: 10.2967/jnumed.122.264977. Epub 2023 Jan 19. J Nucl Med. 2023. PMID: 36657979

2

DOTA-MGS5, a New Cholecystokinin-2 Receptor-Targeting Peptide Analog with an Optimized Targeting Profile for Theranostic Use.

Klingler M, Summer D, Rangger C, Haubner R, Foster J, Sosabowski J, Decristoforo C, Virgolini I, von Guggenberg E. Klingler M, et al. J Nucl Med. 2019 Jul;60(7):1010-1016. doi: 10.2967/jnumed.118.221283. Epub 2018 Dec 7. J Nucl Med. 2019. PMID: 30530828 Free PMC article.

3

Effects of Side Chain and Peptide Bond Modifications on the Targeting Properties of Stabilized Minigastrin Analogs.

Zavvar TS, Hörmann AA, Klingler M, Summer D, Rangger C, Desrues L, Castel H, Gandolfo P, von Guggenberg E. Zavvar TS, et al. Pharmaceuticals (Basel). 2023 Feb 13;16(2):278. doi: 10.3390/ph16020278. Pharmaceuticals (Basel). 2023. PMID: 37052226 Free PMC article.

4

¹¹¹In/⁶⁸Ga-Labeled DOTA-conjugated cyclo[γ-d-Glu-Ala-Tyr-d-Lys]-Trp-Met-Asp-Phe-NH₂ (cyclo-MG1), a minigastrin analog.

Chopra A. Chopra A. 2012 May 17 [updated 2012 Jul 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 May 17 [updated 2012 Jul 12]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22787691 Free Books & Documents. Review.

5

Targeting of the Cholecystokinin-2 Receptor with the Minigastrin Analog ¹⁷⁷Lu-DOTA-PP-F11N: Does the Use of Protease Inhibitors Further Improve In Vivo Distribution?

Sauter AW, Mansi R, Hassiepen U, Muller L, Panigada T, Wiehr S, Wild AM, Geistlich S, Béhé M, Rottenburger C, Wild D, Fani M. Sauter AW, et al. J Nucl Med. 2019 Mar;60(3):393-399. doi: 10.2967/jnumed.118.207845. Epub 2018 Jul 12. J Nucl Med. 2019. PMID: 30002107 Free article.

6

¹¹¹In/⁶⁸Ga-Labeled DOTA conjugated cyclo[γ-d-Glu-Ala-Tyr-d-Lys]-Trp-Nle-Asp-Phe-NH₂ (cyclo-MG2), a minigastrin analog.

Chopra A. Chopra A. 2012 May 17 [updated 2012 Jul 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2012 May 17 [updated 2012 Jul 26]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 22855967 Free Books & Documents. Review.

7

More advantages in detecting bone and soft tissue metastases from prostate cancer using ¹⁸F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE. Pianou NK, et al. Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003 Free article.

8

Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.

Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, Putzer D, Gabriel M, Virgolini I. Traub-Weidinger T, et al. Q J Nucl Med Mol Imaging. 2010 Feb;54(1):52-60. Q J Nucl Med Mol Imaging. 2010. PMID: 20168286 Free article. Clinical Trial.

9

Preliminary PET/CT Imaging with Somatostatin Analogs [⁶⁸Ga]DOTAGA-TATE and [⁶⁸Ga]DOTAGA-TOC.

Satpati D, Shinto A, Kamaleshwaran KK, Sarma HD, Dash A. Satpati D, et al. Mol Imaging Biol. 2017 Dec;19(6):878-884. doi: 10.1007/s11307-017-1072-z. Mol Imaging Biol. 2017. PMID: 28349291

10

Radiopharmaceutical Formulation and Preclinical Testing of ⁶⁸Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial.

Hörmann AA, Klingler M, Rangger C, Mair C, Decristoforo C, Uprimny C, Virgolini IJ, von Guggenberg E. Hörmann AA, et al. Pharmaceuticals (Basel). 2021 Jun 16;14(6):575. doi: 10.3390/ph14060575. Pharmaceuticals (Basel). 2021. PMID: 34208516 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

137 results

Results by year